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Abstract 
 
Objective(s): To estimate the incidence of first pregnancy in women living with 
perinatally-acquired HIV (PHIV) in the UK and to compare pregnancy management and 
outcomes with age-matched women with behaviourally-acquired HIV (BHIV).  
Design: The National Study of HIV in Pregnancy and Childhood (NSHPC) is a 
comprehensive, population-based surveillance study that collects demographic and 
clinical data on all pregnant women living with HIV, their children, and all HIV-infected 
children in the UK & Ireland.  
Methods: The incident rate ratio (IRR) of first pregnancy was calculated for all females 
of reproductive age who had been reported to the NSHPC as vertically infected children. 
These women and their pregnancies were compared to age-matched pregnant women 
with BHIV.  
Results: Of the 630 females with PHIV reported in the UK as children, 7% (45) went on 
to have ≥ 1 pregnancy, with 70 pregnancies reported. The IRR of first pregnancy was 13 
per 1000 woman-years. The BHIV comparison group comprised 118 women (184 
pregnancies). Women with PHIV were more likely to be on cART at conception and 
have a lower baseline CD4 count (p<0.01 for both). In adjusted analysis, PHIV and a low 
baseline CD4 count were risk factors for detectable viral load near delivery; older age at 
conception and being on cART at conception reduced this risk.  
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Conclusions: Women with PHIV in the UK have a low pregnancy incidence, but those 
who become pregnant are at risk of detectable viral load near delivery, reflecting their 
often complex clinical history, adherence and drug resistance issues. 
Keywords: HIV; paediatrics; pregnant women; antiretroviral agents; pregnancy outcome; 
incidence; viral load; perinatal 
 
 
 
 
Introduction  
Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) peaked 
worldwide in 2001-2 and the estimated number of annual new infections has 
subsequently fallen by 52%[1]. Following advances in treatment with combined 
antiretroviral therapy (cART) and the associated increases in life expectancy[2], the first 
generation of young people with perinatally-acquired HIV (PHIV) has now reached 
adulthood[3]. The emphasis of care for young people living with PHIV has therefore 
shifted to transition of care to adult services, continued management of adherence, 
complex resistance, long-term drug toxicity, and sexual, reproductive, and mental 
health[4, 5].  
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In the UK, approximately 1200 pregnancies in women living with HIV are currently 
reported annually, with the MTCT rate at an all-time low of 0.27%[6]; an increasing 
number of pregnancies are now in women with PHIV.  
Several studies in resource-rich settings have investigated pregnancy rates and outcomes 
in women with PHIV[7-14], reporting lower pregnancy incidence rates compared with 
HIV-negative women[7, 9]. Half of the pregnant women living with PHIV in an earlier 
UK case series had adherence problems[12] and US studies have shown higher HIV viral 
load (VL) during pregnancy but similar rates of MTCT compared to women with 
behaviourally-acquired HIV (BHIV)[8, 9, 13]. Being born to a woman with PHIV was an 
independent risk factor for poor fetal and infant growth when compared to being born to 
a woman with BHIV[11, 15]. Several studies have compared women with PHIV to those 
with BHIV to estimate the effects of mode of HIV acquisition on pregnancy and infant 
outcomes[7, 8, 11, 13]; however, such comparisons have been limited by key differences 
between groups regarding age, parity, and treatment era.  
There is growing interest in the health of HIV-exposed but uninfected (HEU) children 
since they have worse health outcomes than HIV-unexposed infants[16]. HEU infants 
born to women with PHIV may be particularly affected since their mothers are more 
likely to have low CD4 counts, detectable viraemia, and AIDS-related morbidity, as well 
as the hitherto unknown effects of maternal immune dysfunction caused by lifelong HIV 
infection on the developing fetus. Additionally, there are concerns regarding potential 
dysfunction of inherited mitochondria in the fetus due to early childhood ART exposure 
of women with PHIV. 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Our aims were to estimate the incidence of first pregnancy in women living with PHIV in 
the UK and Ireland using national surveillance data and to compare their pregnancy 
management and outcomes with those in an age-matched group of women with BHIV, 
with a focus on delivery with detectable VL and adverse pregnancy outcomes.  
Methods 
In the UK and Ireland, data are collected on pregnant women living with HIV and their 
HIV-exposed children and on all HIV-infected children through a comprehensive, 
population-based surveillance study, the National Study of HIV in Pregnancy and 
Childhood (NSHPC); pregnancies in women with diagnosed HIV are notified through a 
quarterly active surveillance scheme regardless of outcome using standardized reporting 
forms from all maternity units[17, 18]. Children are classified as vertically infected if 
reported with known exposure to maternal HIV infection. The dataset used included all 
diagnosed women with at least one pregnancy reported to the NSHPC by September 
2014. 
The NSHPC has London Multi-Centre Research Ethics Committee approval 
(MREC/04/2/009). 
Estimating incidence rates of first pregnancy reported in women with PHIV 
The population considered ‘at-risk’ of pregnancy were all females with PHIV ever 
reported to the NSHPC as children who had not died or gone abroad before their 13th 
birthday. Time ‘at-risk’ of first pregnancy was considered to be from their 13th birthday 
to 30th June 2014 (‘study end date’) or date of censoring.  Time to estimated conception 
date (estimated delivery date minus 280 days for ongoing pregnancies, actual delivery 
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date minus length of gestation for other outcomes) of first pregnancy was calculated for 
reported pregnancies. Individuals without a reported pregnancy were censored at date of 
death or date of last contact with UK health services if lost-to-follow-up or known to 
have gone abroad before study end date. The incidence rate of first pregnancy was also 
calculated for women with PHIV aged 16-24 years, with time ‘at risk’ of first pregnancy 
calculated from their 16th to 25th birthday, or date of death or last contact as applicable if 
this was earlier. 
Comparing pregnancy management and outcomes of women living with 
PHIV and BHIV 
Eligibility criteria for inclusion in the pregnant women with PHIV group were: at least 
one reported pregnancy; reported as vertically infected with no other risk reported; 
diagnosis before their 14th birthday. Forty-five women met these criteria and comprised 
the PHIV group; years of delivery for their pregnancies spanned 2006 to 2014. 
To create an age-matched BHIV pregnant women group, women were considered for 
inclusion if they met the following criteria: first pregnancy reported with estimated or 
actual delivery date in or after January 2006 (in order to align with the time period of the 
deliveries to PHIV women); nulliparous at first reported pregnancy (or missing parity at 
first reported pregnancy with no indication of any previous pregnancy); diagnosed before 
their first reported pregnancy; not reported as vertically infected; diagnosed after their 
13th birthday if mode of acquisition was known or after their 15th birthday if this was 
unknown; aged ≤29 years at estimated conception of first reported pregnancy. There were 
943 women eligible for the BHIV group. 
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Eligible women for both groups were then classified according to age at first reported 
conception (<16, 16-19, 20-24, 25-29 years). In age bands with excess numbers of 
eligible BHIV women, BHIV women were retained randomly to achieve the target of 
three times the number of PHIV women. Forty-five women were in the PHIV pregnant 
women group and the final, age-matched BHIV comparison group comprised 118 
women. 
Definitions 
The first trimester was defined as <13 completed gestational weeks; second as 13-26 
weeks; and third, ≥27 weeks.  
Baseline CD4+ T-cell counts (cells/μl) were the earliest reported measurements during 
pregnancy, CD4+ T-cell counts and HIV viral load measurements (copies/ml) at delivery 
were those taken closest to delivery, either during the third trimester or within seven days 
after delivery. Undetectable VL was defined as an HIV RNA measurement <50 
copies/ml. 
Caesarean sections taking place before rupture of membranes and/or onset of labour were 
classified as elective. Deliveries before 37 completed gestational weeks were considered 
preterm. Low birth weight (LBW) was defined as <2500g[19]. Infant HIV infection 
status was classified as uninfected or infected based on reported PCR or HIV antibody 
results or indeterminate if infection status had not yet been reported or confirmed.  
Congenital abnormalities were classified according to the WHO International 
Classification of Diseases, 10th revision, using information provided by clinicians at 
infant notification and/or follow-up. 
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Statistical analysis 
Proportions calculated among cases were compared using the χ2 or Fisher’s exact test; 
trends in proportions were assessed using the χ2 test-for-trend[20]. For non-normally 
distributed variables, medians were compared using the Wilcoxon-Mann-Whitney 
test[20, 21] and trends in medians using Cuzick's non-parametric test for trend across 
ordered groups[22]. 
Logistic regression models were fitted to calculate estimates of odds ratios (ORs) and 
adjusted odds ratios (aORs) to examine factors associated with detectable VL near 
delivery among pregnancies ending in live birth.  
To account for clustering of data at the woman level (some contributed more than one 
pregnancy), robust standard errors were calculated using a clustered sandwich 
estimator[23]. Multivariable models were developed using a forward-fitting selection 
strategy. Multiple pregnancies ending in live births were treated as a single event, but the 
total number of infants born was included when ‘infant’ is used. Potential collinearity 
between explanatory variables was examined by calculating variance inflation for the 
regression model estimates. 
Data were managed in Access 2010 (Microsoft Corp., Redmond, Washington, USA), 
compiled using R version 2.14.2[24], and analysed using Stata version 13 (Stata Corp. 
LP, College Station, Texas, USA). 
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Results  
Incidence of first reported pregnancy in women with PHIV 
There were 630 women reported to the NSHPC in childhood with PHIV, with total 
follow-up time of 3568 woman-years; 45 (7%) had at least one pregnancy reported. The 
incidence rate of first pregnancy was 13 per 1000 woman-years (95% confidence interval 
[CI]: 9-17 per 1000 woman-years). Age at first estimated conception date ranged from 13 
to 27 years. The incidence rate of first pregnancy in the sub group of 470 PHIV women 
aged 16-24 years was 22 per 1000 woman-years (95% CI: 16-30), with a total follow-up 
time of 1911 woman-years.  
Comparing pregnancy management and outcomes between PHIV and BHIV 
groups 
The 45 women with PHIV had 70 pregnancies reported (21 second pregnancies, three 
third pregnancies and one fourth pregnancy; all singleton). The age-matched BHIV 
comparison group of 118 women had 184 pregnancies (48 second pregnancies, 15 third 
pregnancies, and three fourth pregnancies; (one twin pregnancy with concordant 
outcomes). Women with PHIV were more likely to be born in the UK, younger at first 
conception, and more likely to be living in London than women with BHIV (Table 1). 
Year of birth for the women and year of conception for their reported pregnancies are 
shown in Figure 1.  
In most pregnancies, the women received antenatal cART, though more pregnancies in 
women with PHIV were conceived on cART and had a lower baseline maternal CD4 
count in pregnancy (Table 2).  Median gestation at initiation of cART in pregnancies not 
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conceived on cART was 21 weeks (interquartile range (IQR): 17-24 weeks) in women 
with BHIV and 17 weeks in women with PHIV (IQR: 10-24 weeks) (p=0.03).  Class of 
cART prescribed did not significantly differ between the two groups amongst live births 
and continuing pregnancies: in 14% (8/59) of pregnancies in women with PHIV (‘PHIV 
pregnancies’) and 26% (42/161) of those in women with BHIV (‘BHIV pregnancies’) 
NNRTI-based ART was given; PI-based cART was given in 80% (47/59) of PHIV 
pregnancies and 67% (109/161) of BHIV pregnancies (p=0.18). Drug class differed 
significantly when restricted to pregnancies not conceived on cART: NNRTI-based 
cART was started in 18% (7/39) of PHIV pregnancies and 48% (32/67) of BHIV 
pregnancies; in 74% (29/39) of PHIV pregnancies and in 42% (28/67) of BHIV 
pregnancies, women started PI-based cART (p=0.004).  Overall, in 49% (23/47) of PHIV 
pregnancies with PI-based cART, women received ritonavir-boosted darunavir, whilst for 
BHIV pregnancies with PI-based regimens, ritonavir-boosted lopinavir predominated 
(61%, 66/109). Raltegravir was used significantly more frequently in PHIV pregnancies 
ending in live births or continuing than in BHIV pregnancies: 27% (16/59) versus 0.6% 
(1/162), respectively (p<0.001).  
A higher proportion of PHIV pregnancies ended in termination, whereas more BHIV 
pregnancies ended in miscarriage (13% v 3%) (Table 2). Among live births, there was no 
evidence of a difference in mode of delivery between the two groups or in the proportion 
of preterm deliveries or of LBW in term infants (Table 2).  
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Examining the association between mode of maternal HIV acquisition and 
detectable VL near delivery in live births 
Of those delivering a live-born infant, 20% of women in the BHIV group and 40% of 
those in the PHIV group had detectable VL near delivery (Table 3). Women with PHIV 
with a live birth had significantly greater odds of detectable delivery VL in univariable 
analysis than women with BHIV (p=0.03) (Table 3); age at first conception, age at 
conception in current pregnancy, cART at conception, baseline CD4 <200 cells/µL, and 
PI-containing ART were also associated with detectable VL.  
In the multivariable final model, the significant association with maternal mode of 
acquisition remained, with PHIV pregnancies having 3.22 times higher odds of 
detectable VL near delivery (Table 3). Receipt of a PI-based regimen was also associated 
with increased odds of unsuppressed VL, whilst conception on cART was associated with 
significantly lower odds. There was an indication that maternal CD4 count of <200 
cells/µL was associated with an increased odds of detectable VL (aOR=3.39, p=0.05).  
Infant outcomes 
In the BHIV group, 1.9% (95% CI: 0.34 – 5.4), 3/160 infants) infants had a major 
congenital abnormality versus 5.7% (95% CI: 1.2 – 15.7, 3/53) in those born to women 
with PHIV (p=0.15). Three of the six infants with defects had first trimester exposure to 
ART (two from conception and one from 11 weeks gestation). Overall, only one infant 
was known to be diagnosed with HIV (positive PCR at age ≤72 hours), whose mother 
with PHIV had longstanding adherence issues; 96% (157/163) of infants born to women 
with BHIV were reported as uninfected compared to 97% (56/59) of infants born to 
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women with PHIV. Infant HIV status was not yet reported to the study in the remaining 
4% and 3% of cases, respectively. 
Discussion  
We report an incidence rate of first pregnancy in females with PHIV aged ≥13 of 13 per 
1000 woman-years and 22 per 1000 woman-years when restricted to women aged 16 to 
24 years. The NSHPC is a longstanding national surveillance study to which all 
pregnancies to women diagnosed with HIV and all children exposed to and diagnosed 
with HIV in the UK and Ireland are reported. In the UK, antenatal HIV screening 
coverage exceeds 95% and reporting to the NSHPC is embedded within NHS-
commissioned antenatal services. We were therefore able to estimate a national incidence 
rate of first pregnancy in young women with PHIV for the first time. We identified some 
significant differences between pregnancies in women with PHIV and those in age-
matched women with BHIV, including more conceptions on cART, lower CD4 counts, 
and more terminations in the PHIV group. We also found that maternal PHIV was an 
independent risk factor for detectable delivery VL, associated with a three-fold increased 
risk.  
Our methodology, whereby our study population of women with PHIV had first been 
reported to the NSHPC in childhood with prospective follow-up, ensures confidence 
about reported mode of acquisition, which can be subject to recall bias. Our estimated 
first pregnancy incidence rate is lower than that reported in two US studies, which found 
incidence rates of 19 and 53 pregnancies per 1000 woman-years in females with PHIV 
aged 13 and above[7, 9]. Our rate here is also low compared with the conception rate in 
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England & Wales among similar age groups, which was 41 per 1000 in women aged 
under 20 and 96 per 1000 in those aged 20-24 years in 2013[25].  
Conception rates are influenced by sexual activity, procreational intent, fertility, and 
access to and use of contraception. Prevalence of sexual activity and risk-taking 
behaviour in young people with PHIV varies by setting. There have been several studies 
in the US: one multi-centre cohort study found lower rates of sexual activity in young 
people with PHIV compared to those with BHIV, with sexual activity more likely in 
those older, those with a boyfriend or girlfriend, and those using illicit drugs[26]; 
however, a smaller single-centre study found similar sexual risk behaviours in young 
people with PHIV and those with BHIV[27], whilst another cohort comparing young 
people with PHIV to those HEU found a lower proportion sexually active in the former, 
but this did not reach statistical significance[28]. In the UK, one single-centre cohort 
reported that 78% of young people with PHIV aged 16 to 25 were sexually active[29], 
and the AAPLHI cohort reported lower sexual activity in adolescents with PHIV 
compared with HIV-negative adolescents[30]. A qualitative study of young people with 
PHIV showed a high rate of procreational intent, likely reflecting perceived 
improvements in HIV treatment and MTCT risk[31]. A small, single-centre cohort of 
young women with PHIV found that 14% had a diagnosis of infertility[32]. Therefore, 
lower incidence of first pregnancy in women with PHIV compared to women of a similar 
age in the general UK population may be multifactorial: lower rates of sexual activity and 
lower fertility due to lifelong HIV and its associated morbidity.  
However, although the proportion of live births was similar across groups, there were 
more reported terminations in women with PHIV, potentially reflecting differences in 
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clinical care: women with PHIV may access care more often since they are more likely to 
have had AIDS-related morbidity, drug resistance, and adherence issues[12], so 
pregnancies ending in early termination may be better ascertained and reported by our 
respondents than similar pregnancies in women with BHIV. This difference could also 
reflect lower fertility desires and/or a higher unmet need for contraception. Reduction of 
unintended pregnancies through provision of contraception and reproductive health 
services is a key strategy in preventing perinatal HIV in resource-rich and resource-poor 
settings[33, 34]. A higher proportion of terminations in the PHIV group indicates 
potential need for more closely integrated family planning services. As women with 
PHIV may experience fragmentation of care during transition from paediatric to adult 
services, it is critical to ensure their reproductive health needs are met throughout this 
period and across healthcare settings. 
Women with PHIV were more likely to conceive on cART, reflecting their childhood 
diagnosis and treatment experience. Gestation at cART initiation in those untreated at 
conception was earlier in women with PHIV than women with BHIV (median 17 and 21 
weeks, respectively), despite no difference in gestation at antenatal booking (all women 
had been diagnosed with HIV before their first pregnancy). This may have been because 
women with PHIV are more strongly linked to HIV care, or because their physicians 
anticipated slow VL decay or suboptimal adherence.  
Young people with PHIV have higher risk of treatment failure and multiclass drug 
resistance than those with BHIV for many reasons: previous exposure to obsolete and 
suboptimal ART; the limited range of ART licensed for paediatric use; difficulties with 
adherence because of stigma, discrimination, and HIV-associated neurocognitive deficits, 
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among others[35]. These factors may be implicated in the association we and others 
report between having PHIV and failing to achieve undetectable VL by delivery[8, 13]. 
Though we do not report on treatment history or resistance, our finding of more 
raltegravir use among the PHIV group is suggestive of more complex treatment profiles 
or higher VL in pregnancy in this group. We also found that older age and conception on 
cART were associated with reduced risk of detectable VL near delivery overall, 
consistent with findings from elsewhere[36, 37].  
We found no significant difference in preterm delivery or LBW in term infants between 
PHIV and BHIV groups. In a US study, women with PHIV had a nearly six-fold 
increased risk of having a small-for-gestational-age infant compared with BHIV 
women[15] and the same research group found that infants born to women with PHIV 
had shorter length-for-age one year after birth[11]. This inconsistency may be because 
our BHIV comparison group was restricted to women diagnosed before conception who 
were nulliparous at first included pregnancy; the US studies did not account for 
differences in gravidity or comment on timing of diagnosis. Although a higher proportion 
of infants with mothers with PHIV had birth defects in our study, this difference was not 
statistically significant and based on small numbers.  
Of note, the large majority of mothers with PHIV in the UK were born prior to 1994 
when antiretroviral prophylaxis for PMTCT started being used. It will be important to 
continue to monitor the long-term health of HEU infants born to women with PHIV. 
Ideally, the comparison group would also have been matched to the PHIV group by 
country of birth, but low numbers of BHIV women with younger age at first conception 
precluded this. Although the study does collect ‘baseline’ VL data from the beginning of 
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pregnancy, there was a considerable proportion of missing data so we were unable to 
include it in our analysis. There may have been under-reporting of pregnancies ending in 
early termination or miscarriage that did not come to the attention of our respondents in 
antenatal care settings for both BHIV and PHIV women. Thus, the incidence of first 
pregnancy reported here is a minimum estimate and median age at first conception could 
be lower than our estimate. We were unable to calculate an incidence of first pregnancy 
in BHIV women since the study does not collect data on women who do not become 
pregnant. 
As previously noted, differences in case ascertainment may exist between the two groups, 
as women with PHIV may be more closely monitored. Since we do not routinely collect 
information on smoking, other substance use, hypertension, prior treatment history, or 
measures of adherence, we were unable to account for these factors. The sample size 
limitations in our study mean that differences in low-prevalence adverse birth outcomes 
may not have been detected. In terms of generalizability, our data are national and 
therefore representative.  
As cohorts of women with PHIV continue to age, and since younger women and 
adolescents with PHIV have accessed better treatment and therefore have improved 
health status, the incidence of planned pregnancy in women with PHIV is likely to rise, in 
keeping with high rates of procreational intent reported in young people with PHIV in the 
UK[31]. However, the current cohort of adolescents with PHIV have reported low rates 
of sexual activity; if recent work on improving transition from paediatric to adult services 
increases access to and use of effective contraception [38], incidence of unplanned 
pregnancy in this group may fall. It is imperative that the complex health needs of women 
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with PHIV before, during, and after pregnancy are recognised and addressed. We have 
demonstrated that women with PHIV in the UK are less likely to achieve an undetectable 
VL in pregnancy, but further work on larger cohorts is required to establish the effects of 
perinatal HIV infection on fertility and on pregnancy/birth outcomes in the current 
treatment era. Our findings confirm a need to closely follow and support this group of 
women living with PHIV in their reproductive years and beyond, as their health status 
and often complex treatment profile have implications for a second generation of 
perinatally infected and HEU children.
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Figure	1.	
A. Year	of	birth	and	year	of	conception	in	118	women	with	BHIV	and	their	184	reported	pregnancies	
B. Year	of	birth	and	year	of	conception	in	45	women	with	PHIV	and	their	70	reported	pregnancies	
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Table 1 Baseline characteristics of 118 women with BHIV & 45 women with PHIV
* Women with injecting drug use as likely route of acquisition of HIV
IQR: interquartile range
Women with 
BHIV (N=118)
Women with 
PHIV (N=45)
n % n % p-value
Ethnic group 0.43
   White 37 32 11 24
   Black African 67 57 26 58
   Other 13 11 8 18
Region of birth 0.02
   UK/Ireland 41 36 26 58
   Africa 62 54 18 40
   Elsewhere 12 10 1 2
Injecting drug use* 3 3 0 0 0.28
Median age at diagnosis (years) (IQR) 19.1 (17.4, 20.5) 5.6 (2.7, 11.1) <0.01
Median age at first conception (years) (IQR) 20.1 (18.8, 23.0) 19.8 (17.7, 21.4) 0.02
Age at first conception (years, grouped) -
   <16 0 0 3 7
   16-19 64 54 24 53
   20-24 48 41 16 36
   25-29 6 5 2 4
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Table 2 Clinical factors and pregnancy outcomes in women with PHIV and BHIV
             
*There was one twin pregnancy in the PHIV group ending in live birth, so total 59 infants were 
born in this group.
**Pregnancies ending in live birth or continuing to term only
# Pregnancies ending in live birth
IQR: interquartile range
NB: lower than expected denominators indicate missing data
Pregnancies in 
women with BHIV 
(N=184)
Pregnancies in 
women with PHIV 
(N=70)
n % n % p-value
On ART at conception
(n=181)
69 39
(n=69)
45 65    <0.01
Type of antenatal ART (n=178) (n=69)
   None 5 3 4 6 0.32
   Monotherapy 4 2 0 0
   cART 169 95 65 94
Baseline CD4 in pregnancy
(cells/µL)
(n=171) (n=66)
   500 63 37 21 32 <0.01
   350-499 54 31 9 14
   200-349 44 26 22 33
   <200 10 6 14 21
Outcome of pregnancy (n=184) (n=70)
   Live birth 163 88.5 58* 83 0.02
   Stillbirth 1 0.5 0 0
   Miscarriage 12 6 2 3
   Termination 5 3 9 13
   Continuing 3 1 1 1
Median weeks gestation at 
booking**, (IQR)
(n=115)
12.1(10.3, 15.4)
(n=57)
11.6 (9.4, 13.9)
Mode of delivery# (n=163) (n=56)
   Vaginal 57 35 18 32 0.88
   Elective caesarean section 61 37 23 41
   Emergency caesarean section 45 24 15 27
Preterm delivery# (n=163) (n=56)
   <37 weeks gestation 20 12 9 16 0.47
   ≥37 weeks gestation 143 88 47 84
Low birth weight in term 
infants#
(n=139) (n=46)
   <2500g 12 9 3 7 0.65
   ≥2500g 127 91 43 93
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Table 3 Risk factors for having a detectable viral load near to delivery in live births
Explanatory variable
Viral load >50 
copies/ml 
Univariable Analysis Multivariable analysis (n=206)
N (%) OR 95% CI p -value aOR 95% CI p-value
Maternal HIV acquisition
BHIV 32/158 (20) 1 1
PHIV 22/55 (40) 2.63 1.24 - 5.55 0.01* 3.22 1.22 - 8.48 0.02*
Age at first conception
(continuous, per year older) 0.83 0.73 - 0.95 <0.01* - - -
Parity
Nulliparous 37/127 (29) 1 - - -
Multiparous 17/86 (20) 0.41 0.34 - 1.07 0.08 - - -
Previous AIDS-defining illness**
No 22/101 (22) 1 - - -
Yes 7/12 (58) 5.03 1.32 - 19.17 0.02* - - -
Age at conception 
(continuous, per year older) 0.80 0.71 - 0.90 <0.01* 0.89 0.78 - 0.99 0.04*
Maternal region of birth
UK/Ire./Europe 26/89 (29) 1 - - -
Africa/Elsewhere 28/121 (23) 0.73 0.36 - 1.47 0.38 - - -
CD4 count near conception
≥500 cells/µL 13/80 (16) 1 1
200-499 cells/µL 29/111 (26) 1.82 0.97 - 3.82 0.11 1.97 0.86 - 4.51 0.11
<200 cells/µL 10/19 (53) 5.73 1.59 - 20.61 0.01* 3.49 1.00 - 12.10 0.05
On ART at conception
No 40/113 (35) 1 1
Yes 13/99 (13) 0.28 0.12 - 0.62 <0.01* 0.27 0.11 - 0.70 <0.01*
PI-containing ART
No 4/48 (8) 1 1
Yes 48/161 (30) 4.67 1.64 - 13.34 <0.01* 3.52 1.16 - 10.69 0.03*
Gestational age at delivery
≥ 37 weeks 44/184 (24) 1 -
< 37 weeks 10/29 (34) 1.67 0.76 - 3.70 0.20 - - -
Year of delivery
2006-2008 18/63 (29) 1 - - -
2009-2011 21/84 (25) 0.83 0.40 - 1.75 0.63 - - -
2012-2014 15/66 (23) 0.74 0.33 - 1.63 0.45 - - -
*P-value reaches the level of significance (<0.05)
** The variable ‘previous AIDS-defining illness’ has a high proportion of missing data and so was not included in the multivariable analysis
OR: odds ratio, aOR: adjusted odds ratio, CI: confidence interval
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
